Results 111 to 120 of about 290,519 (311)
A demência é uma das 10 causas de mortalidade no mundo, que tende a aumentar com o envelhecimento da população. A doença de Alzheimer é caracterizada pela degeneração de neurônios na região do hipocampo e do córtex cerebral, áreas responsáveis por ...
Vitória Brunel Selinger +3 more
doaj
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Adam P, Mecca, Christopher H, van Dyck
openaire +3 more sources
Systemic Extracerebral Atherosclerotic Burden and Dementia Risk After Incident Stroke
ABSTRACT Background Stroke survivors are at increased risk of dementia, but clinically accessible markers of risk heterogeneity remain limited. Previous studies have largely examined atherosclerotic disease in individual vascular beds rather than the overall burden of systemic extracerebral atherosclerosis.
Zhexuan Yu +4 more
wiley +1 more source
ABSTRACT Objective Minor strokes may be associated with early neurological deterioration (END) and disabilities. The objective was to investigate the role of serum glial fibrillary acidic protein (GFAP) levels in predicting END. Methods Data originated from a multicenter cohort study conducted prospectively.
Jie Zhou +45 more
wiley +1 more source
Background: Urinary incontinence is a common problem in Alzheimer's patients that significantly affects the quality of life and well-being of the sufferers.
Giovanni Iga Firmanda +2 more
doaj +1 more source
Stage‐Specific Patterns of Imaging and Non‐Motor Biomarkers in Spinocerebellar Ataxia Type 3
ABSTRACT Objective Advancements in disease‐modifying therapies for spinocerebellar ataxia Type 3 (SCA3) underscore the need for robust biomarkers to monitor disease progression and evaluate treatment efficacy. Although motor phenotypes have been well characterized, less is known about non‐motor and imaging‐based features across different disease stages.
Chun Li +17 more
wiley +1 more source
The Association of Amyloid‐β and Tau With Synaptic Dysfunction in Alzheimer's Disease
ABSTRACT Objective To clarify the relative contributions of amyloid and tau to synaptic dysfunction in Alzheimer's disease (AD). Methods We included 109 cognitively unimpaired and impaired individuals from the Geneva Memory Center with available CSF synaptic biomarkers (neurogranin, SNAP‐25, GAP‐43). Participants were stratified according to amyloid (A)
Fausto Roveta +11 more
wiley +1 more source
Alzheimer\u2019s Disease and Related Dementias [Spanish]
Alzheimer\u2019s Disease and Related Dementias [Spanish]\ubfQu\ue9 es la enfermedad de Alzheimer? -- \ubfQui\ue9n la tiene? -- Lo que sabemos -- C\uf3mo reconocer los signos de la enfermedad de Alzheimer -- C\uf3mo se trata -- Apoyo para la familia y los
core
A Two‐Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p‐Tau217 Gray Zone
ABSTRACT Objective Plasma p‐Tau217 leaves 30%–50% of patients in an indeterminate “gray zone” often requiring Aβ‐PET. We developed GRAD (Gatekeeper‐Reflex for Alzheimer's Disease), a two‐stage Aβ‐positivity prediction model to improve classification while reserving Aβ‐PET for residual uncertainty.
Harthik Parankusham +7 more
wiley +1 more source

